Related Experiment Videos
Arsenic trioxide: acute promyelocytic leukemia and beyond
T Bachleitner-Hofmann1, M Kees, H Gisslinger
1Department of Internal Medicine 1, University of Vienna, Austria.
Leukemia & Lymphoma
|October 29, 2002
Summary
Arsenic trioxide (As2O3) effectively treats acute promyelocytic leukemia (APL) by inducing apoptosis. Emerging research suggests As2O3 also shows promise against non-APL hematologic and solid tumors, with potential enhancement strategies being explored.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Arsenic trioxide (As2O3) has a long history in medicine.
- As2O3 is a successful treatment for acute promyelocytic leukemia (APL), inducing apoptosis in leukemic cells.
- Recent findings indicate As2O3's apoptotic effects extend beyond APL to other malignant cells.
Purpose of the Study:
- To review the historical use, current applications, and future potential of As2O3 therapy.
- To emphasize the role of As2O3 in treating non-APL hematologic and solid malignancies.
- To discuss agents that can enhance As2O3 sensitivity in less responsive tumors.
Main Methods:
- Literature review of arsenic trioxide (As2O3) in cancer treatment.
- Analysis of studies on As2O3's mechanism of action, particularly apoptosis induction.
- Examination of clinical data and research on As2O3 for both APL and non-APL cancers.
Main Results:
- As2O3 is a highly effective treatment for acute promyelocytic leukemia (APL).
- As2O3 demonstrates apoptotic effects on various malignant cells, including non-APL types.
- Ascorbic acid and other agents may enhance As2O3 sensitivity in resistant tumors.
Conclusions:
- Arsenic trioxide (As2O3) holds significant therapeutic potential beyond APL, including for solid tumors.
- Further research into As2O3's efficacy and enhancement strategies is warranted for broader oncological applications.
- As2O3 represents a promising agent for future cancer treatment regimens.